This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wheless, J. W. Search for Related Content PubMed PubMed Citation Articles by Wheless, J. W. Social Bookmarking                         What's this?

Use of Topiramate in Childhood Generalized Seizure Disorders

Texas Comprehensive Epilepsy Program, Department of Neurology, University of Texas-Houston, 6431 Fannin Street, Suite 70-1-4, Houston, TX 77030, jamesw.whelessCuth.tmc.edu

Topiramate is a sulfamate derivative of the naturally occurring monosaccharide D-fructose. It was initially approved in the United States as adjunctive therapy for partial seizures in 1997. However, there is increasing evidence that it is effective in the treatment of generalized seizures and epilepsy syndromes. Initially, open-label studies using topiramate as add-on therapy in children with refractory generalized seizure types were performed. These showed improvement in patients with the following generalized seizure types: typical and atypical absence, atonic, myoclonic, generalized tonic-clonic, and juvenile myoclonic epilepsy. Double-blind, placebo-controlled multicentered studies in patients with refractory primary generalized tonic-clonic seizures and epilepsy syndromes were performed. The median reduction in seizure frequency for primary generalized tonic-clonic seizures was 56.7% for topiramate and 9% for placebo. Additionally, 13.6% of topiramate-treated patients were primary generalized tonic-clonic seizure free for the study period. In the topiramate-treated juvenile myoclonic epilepsy patients, primary generalized tonic-clonic seizures were reduced >50% in 73% of patients. Open-label extension showed that primary generalized tonic-clonic seizures were reduced >50% in 63% of topiramate-treated patients for 6 months, and 16% were primary generalized tonic-clonic seizure free 6 months. Accumulating evidence suggests that topiramate has a broad spectrum of antiepileptic effect. Moreover, life-threatening organ toxicity has not been attributed to topiramate. Topiramate is an effective treatment for refractory generalized seizure types and epilepsy syndromes encountered in children. (J Child Neurol 2000;15:S7-S13).

Journal of Child Neurology, Vol. 15, No. 1 suppl, S7-S13 (2000)
DOI: 10.1177/088307380001500103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Grosso, E. Franzoni, P. Iannetti, G. Incorpora, C. Cardinali, I. Toldo, A. Verrotti, F. C. Moscano, V. Lo Faro, L. Mazzone, et al. Efficacy and Safety of Topiramate in Refractory Epilepsy of Childhood: Long-Term Follow-Up Study J Child Neurol, November 1, 2005; 20(11): 893 - 897. [Abstract] [PDF]

				N. Watemberg, H. Goldberg-Stern, B. Ben-Zeev, I. Berger, R. Straussberg, S. Kivity, U. Kramer, N. Brand, and T. Lerman-Sagie Clinical Experience With Open-Label Topiramate Use in Infants Younger Than 2 Years of Age J Child Neurol, April 1, 2003; 18(4): 258 - 262. [Abstract] [PDF]